Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-25-001361
Filing Date
2025-05-19
Accepted
2025-05-19 17:01:55
Documents
62
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q eyen-20250331x10q.htm   iXBRL 10-Q 1051279
2 EX-31.1 eyen-20250331xex31d1.htm EX-31.1 15813
3 EX-32.1 eyen-20250331xex32d1.htm EX-32.1 6523
4 EX-32.2 eyen-20250331xex32d2.htm EX-32.2 5612
  Complete submission text file 0001410578-25-001361.txt   5186328

Data Files

Seq Description Document Type Size
5 EX-101.SCH eyen-20250331.xsd EX-101.SCH 55346
6 EX-101.CAL eyen-20250331_cal.xml EX-101.CAL 43980
7 EX-101.DEF eyen-20250331_def.xml EX-101.DEF 146232
8 EX-101.LAB eyen-20250331_lab.xml EX-101.LAB 345510
9 EX-101.PRE eyen-20250331_pre.xml EX-101.PRE 273218
65 EXTRACTED XBRL INSTANCE DOCUMENT eyen-20250331x10q_htm.xml XML 840696
Mailing Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017
Business Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017 813-766-9539
EYENOVIA, INC. (Filer) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38365 | Film No.: 25964912
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)